Co-Diagnostics Inc (NASDAQ:CODX) has said it will be presenting on direct saliva testing for coronavirus (COVID-19) at the 28th Annual International Molecular Medicine Tri-Conference, to be held virtually between February 16-18, 2021.
Representatives of the molecular diagnostics specialist will introduce the Co-Diagnostics Logix Smart SARS-CoV-2 DS (Direct Saliva) kit, which the company has submitted for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA).
READ: Co-Diagnostics completes FDA submission for Emergency Use Authorization for its Logix Smart SARS-CoV-2 DS (Direct Saliva) test
The virtual presentation, which will be webcast at 4.30pm Eastern Time (ET) on February 16, will include a description of the test technology, its workflow processes, and the engineering process involved in its development, as well as a test demonstration, Co-Diagnostics said, adding that it will also participate in a Q&A panel at 4.50pm ET with other industry and academic experts in SARS-CoV-2 molecular diagnostic testing.
“We are honored to introduce this cutting-edge technology to the international molecular diagnostics industry at Tri-Con. The company believes direct saliva has the potential to greatly improve COVID-19 testing throughput while delivering lower processing costs and increased accessibility of gold-standard PCR diagnostics worldwide, including point-of-care and “at home” applications for businesses, schools, and home settings”, Co-Diagnostics chief executive Dwight Egan said in a statement.
“This direct saliva test is another illustration of our core belief that affordable, fast, accurate and accessible surveillance and diagnostic solutions should be available everywhere, which includes the use of testing technology that gives individuals the power to know their correct COVID-19 status quickly, and inexpensively. Our direct saliva test technology was developed specifically to address the efficiency demands of high-throughput lab applications as well as the accessibility imperatives of the point-of-care and “at home” markets. As populations around the world go back to the office, as students go back to school, as people again travel and participate in entertainment venues, we believe this direct saliva technology will help ensure “COVID-safe” environments through fast, accurate, affordable and accessible testing solutions”, the CEO added.
The Molecular Med Tri-Con is presented by the Cambridge Healthtech Institute and is regarded as the most comprehensive, industry-leading event covering precision medicine and diagnostics.
Contact the author at calum@proactiveinvestors.com
Follow him on Twitter @Cal_Proac